Merck & Co. (MRK) Earns “Market Perform” Rating from Leerink Swann
MRK has been the subject of a number of other reports. Piper Jaffray Cos. restated a neutral rating and issued a $62.00 price objective (up from $58.00) on shares of Merck & Co. in a report on Monday, August 8th. Vetr downgraded Merck & Co. from a buy rating to a hold rating and set a $64.84 price objective for the company. in a report on Monday, October 10th. Argus restated a buy rating and issued a $65.00 price objective on shares of Merck & Co. in a report on Wednesday, September 14th. Jefferies Group restated a hold rating and issued a $56.00 price objective (down from $57.00) on shares of Merck & Co. in a report on Monday, September 12th. Finally, BMO Capital Markets downgraded Merck & Co. from an outperform rating to a market perform rating and set a $62.00 price objective for the company. in a report on Monday, July 18th. They noted that the move was a valuation call. Twelve research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of €65.58 ($72.87).
Merck & Co. (NYSE:MRK) traded down 0.87% during mid-day trading on Wednesday, hitting $61.60. The company’s stock had a trading volume of 1,830,521 shares. The firm has a 50 day moving average of $62.56 and a 200-day moving average of $58.70. The firm has a market cap of $170.34 billion, a price-to-earnings ratio of 33.79 and a beta of 0.68. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $64.86.
Merck & Co. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.02. The company earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The company’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 earnings per share. On average, equities research analysts expect that Merck & Co. will post $3.75 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 15th were paid a $0.46 dividend. The ex-dividend date was Tuesday, September 13th. This represents a $1.84 annualized dividend and a yield of 2.96%. Merck & Co.’s dividend payout ratio (DPR) is 101.10%.
In other news, insider Weir Mirian M. Graddick sold 40,800 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the completion of the sale, the insider now owns 128,973 shares in the company, valued at approximately €8,005,354.11 ($8,894,837.90). The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Kenneth C. Frazier sold 392,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the sale, the chairman now owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the company. Alexandria Capital LLC raised its stake in shares of Merck & Co. by 43.8% in the first quarter. Alexandria Capital LLC now owns 24,435 shares of the company’s stock valued at $1,293,000 after buying an additional 7,439 shares during the last quarter. Mn Services Vermogensbeheer B.V. bought a new stake in shares of Merck & Co. during the first quarter valued at about $3,251,000. Commonwealth Equity Services Inc raised its stake in shares of Merck & Co. by 3.6% in the first quarter. Commonwealth Equity Services Inc now owns 845,044 shares of the company’s stock valued at $44,711,000 after buying an additional 29,679 shares during the last quarter. River Wealth Advisors LLC raised its stake in shares of Merck & Co. by 2.3% in the first quarter. River Wealth Advisors LLC now owns 17,543 shares of the company’s stock valued at $928,000 after buying an additional 390 shares during the last quarter. Finally, John G Ullman & Associates Inc. raised its stake in shares of Merck & Co. by 1.3% in the first quarter. John G Ullman & Associates Inc. now owns 225,672 shares of the company’s stock valued at $11,940,000 after buying an additional 2,840 shares during the last quarter. Institutional investors own 72.93% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.